Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF
Posted inCardiology Nephrology news

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline KDIGO kidney risk category, while maintaining a manageable safety profile.
Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial
Posted inCardiology Nephrology news

Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial

The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven by intraglomerular pressure modulation rather than systemic vascular remodeling.
Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety
Posted inDiabetes & Endocrinology Nephrology news

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type 2 diabetes trials and a manageable hyperkalemia signal.